![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
|
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
10MB | |
![[img]](http://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Material)
25kB |
| Item Type: | Article |
|---|---|
| Title: | Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis |
| Creators Name: | Schmidt, O. and Nehls, N. and Prexler, C. and von Heyking, K. and Groll, T. and Pardon, K. and Garcia, H.D. and Hensel, T. and Gürgen, D. and Henssen, A.G. and Eggert, A. and Steiger, K. and Burdach, S. and Richter, G.H.S. |
| Abstract: | BACKGROUND: Histone acetylation and deacetylation seem processes involved in the pathogenesis of Ewing sarcoma (EwS). Here histone deacetylases (HDAC) class I were investigated. METHODS: Their role was determined using different inhibitors including TSA, Romidepsin, Entinostat and PCI-34051 as well as CRISPR/Cas9 class I HDAC knockouts and HDAC RNAi. To analyze resulting changes microarray analysis, qRT-PCR, western blotting, Co-IP, proliferation, apoptosis, differentiation, invasion assays and xenograft-mouse models were used. RESULTS: Class I HDACs are constitutively expressed in EwS. Patients with high levels of individual class I HDAC expression show decreased overall survival. CRISPR/Cas9 class I HDAC knockout of individual HDACs such as HDAC1 and HDAC2 inhibited invasiveness, and blocked local tumor growth in xenograft mice. Microarray analysis demonstrated that treatment with individual HDAC inhibitors (HDACi) blocked an EWS-FLI1 specific expression profile, while Entinostat in addition suppressed metastasis relevant genes. EwS cells demonstrated increased susceptibility to treatment with chemotherapeutics including Doxorubicin in the presence of HDACi. Furthermore, HDACi treatment mimicked RNAi of EZH2 in EwS. Treated cells showed diminished growth capacity, but an increased endothelial as well as neuronal differentiation ability. HDACi synergizes with EED inhibitor (EEDi) in vitro and together inhibited tumor growth in xenograft mice. Co-IP experiments identified HDAC class I family members as part of a regulatory complex together with PRC2. CONCLUSIONS: Class I HDAC proteins seem to be important mediators of the pathognomonic EWS-ETS-mediated transcription program in EwS and in combination therapy, co-treatment with HDACi is an interesting new treatment opportunity for this malignant disease. |
| Keywords: | Ewing Sarcoma, Class I HDACs, Expression Profiles, Pathogenesis, Targeted Therapy, Animals, Mice |
| Source: | Journal of Experimental & Clinical Cancer Research |
| ISSN: | 1756-9966 |
| Publisher: | BioMed Central |
| Volume: | 40 |
| Number: | 1 |
| Page Range: | 322 |
| Date: | 15 October 2021 |
| Additional Information: | Erratum in: J Exp Clin Canc Res 41: 7. |
| Official Publication: | https://doi.org/10.1186/s13046-021-02125-z |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
Download Statistics
Download Statistics
